Australia flags rare eye risk tied to GLP-1 diabetes/weight drugs
TL;DR Summary
Australia’s TGA warns of a rare but serious eye disorder called NAION linked to GLP-1 medicines such as Ozempic, Wegovy and Mounjaro; 36 cases have been reported (23 with Ozempic/Wegovy, 10 with Mounjaro, 3 with Saxenda), prompting updated safety warnings but no prescription restrictions. Patients should seek urgent medical attention for sudden vision loss, while doctors are advised not to stop treatment without consultation. Novo Nordisk says the benefit–risk profile remains favorable given the drugs’ overall impact on diabetes and obesity.
- Australian regulator warns of ‘rare but severe’ eye disorder linked to GLP-1 drugs like Ozempic The Guardian
- Rare eye disorder linked to Ozempic-like medications ABC News & Headlines – Australian Broadcasting Corporation
- Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness WSB-TV
- TGA issues new warning after finding link between GLP-1 medicines Ozempic, Wegovy, Mounjaro to eye disorder The West Australian
- GLP-1 RA Use Linked to Higher Risk for Ischemic Optic Neuropathy Neurology Advisor
Reading Insights
Total Reads
1
Unique Readers
7
Time Saved
3 min
vs 3 min read
Condensed
86%
587 → 81 words
Want the full story? Read the original article
Read on The Guardian